Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs OSI 211 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 16 Mar 2010 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov record.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Sep 2005 New trial record.